Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference
Polaryx Therapeutics (Nasdaq: PLYX) will participate in the 25th Annual Needham Virtual Healthcare Conference, hosting one-on-one investor meetings April 13–16, 2026 and a group presentation on April 16, 2026 at 10:15 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Polaryx Therapeutics (Nasdaq: PLYX) will participate in the 25th Annual Needham Virtual Healthcare Conference, hosting one-on-one investor meetings April 13–16, 2026 and a group presentation on April 16, 2026 at 10:15 a.m. ET.
Live webcasts and archived replays will be available in the Investors Relations "News and Events" section at the company website.
Details
News Market Reaction – PLYX
On Apr 1, the day this news came out, PLYX closed 0.53% above the previous close.
Data tracked by StockTitan Argus for the Apr 1 session.
Key Figures
- Share price
- $7.56
- Pre-news close, PLYX share price
- Market cap
- $312,939,193
- Pre-news equity value based on current price
- Shares outstanding
- 47,343,297 shares
- Common shares outstanding as of Feb 1, 2026 (10-K)
- Major holder stake
- 22,744,796 shares (48.0%)
- Group led by Mstone and Alex Keun Mo Yang (Schedule 13D)
- Aggregate purchase price
- $3,000,513
- Total cost for major holder’s currently owned shares (Schedule 13D)
- Insider purchase
- 2,867 shares at $2.7871
- CFO open-market buy on Feb 18, 2026 (Form 4)
- CFO direct holdings
- 228,225 shares
- CFO stake after Feb 18, 2026 purchase (Form 4)
- Conference presentation time
- 10:15 a.m. ET
- Group presentation at 25th Annual Needham Virtual Healthcare Conference
Historical Context
-
FDA Fast Track designation for PLX-200 in CLN2 disease.
-
Expanded engagement with Krabbe community and SOTERIA trial update.
-
Rare Disease Day activities and reaffirmed commitment to LSD patients.
-
CRO selected for SOTERIA Phase 2 basket trial of PLX-200.
-
Preclinical PLX-200 data for Krabbe disease presented at WORLDSymposium.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
lysosomal storage disorders medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
PARAMUS, NJ, April 01, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), announces that members of the executive team will be participating in the 25th Annual Needham Virtual Healthcare Conference.
Format: Polaryx management will host one-on-one investor meetings as well as a group presentation
Dates:
One‑on‑one meetings: Monday, April 13, 2026 through Thursday, April 16, 2026
Group presentation: Thursday, April 16, 2026 at 10:15 a.m. ET
To schedule a meeting, please contact your Needham & Company, LLC representative.
Live webcasts of the presentations will be available under “News and Events” in the Investors Relations section of the Company’s website at https://investors.polaryx.com/. Replays of the webcasts will be archived and available following the events.
About Polaryx Therapeutics
Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing patient-friendly small molecule and gene therapy treatments for rare orphan lysosomal storage disorders (LSDs). Founded in 2014, Polaryx seeks to deliver safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs. Our small molecule drug candidates share similar modes of action that have been demonstrated to address lysosomal dysfunction, neuroinflammation, and neuronal loss in our validated animal models that closely mimic human clinical phenotypes. Our most advanced product candidate, PLX-200, targets several LSDs and we intend to launch SOTERIA, a Phase 2 basket trial, to evaluate PLX-200’s safety and efficacy. For more information, please visit www.polaryx.com.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, statements regarding: Polaryx’s clinical development plans for PLX-200, including the timing for initiation of the SOTERIA trial. Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Polaryx believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Polaryx’s filings with the U.S. Securities and Exchange Commission (the SEC), many of which are beyond the company’s control and subject to change. Actual results could be materially different. Risks and uncertainties include: global macroeconomic conditions and related volatility, expectations regarding the initiation, progress, and expected results of Polaryx’s clinical trials; expectations regarding the timing, completion and outcome of Polaryx’s clinical trials; the timing or likelihood of regulatory filings and approvals; liquidity and capital resources; and other risks and uncertainties identified in Polaryx’s Registration Statement on Form S-1, as amended, filed with the SEC on January 27, 2026 and subsequent disclosure documents Polaryx may file with the SEC. Polaryx claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Polaryx expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.
Media Contact:
CORE IR
(212) 655-0924
media@polaryx.com
Investor Contact:
CORE IR
(212) 655-0924
inestor@polaryx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.